Neurocrine Biosciences, Inc. - Common Stock (NBIX)
130.10
+0.00 (0.00%)
NASDAQ · Last Trade: Feb 20th, 7:13 AM EST
Detailed Quote
Previous Close
130.10
Open
-
Bid
121.42
Ask
137.00
Day's Range
N/A - N/A
52 Week Range
84.23 - 160.18
Volume
0
Market Cap
13.02B
PE Ratio (TTM)
27.92
EPS (TTM)
4.7
Dividend & Yield
N/A (N/A)
1 Month Average Volume
1,252,107
Chart
About Neurocrine Biosciences, Inc. - Common Stock (NBIX)
Neurocrine Biosciences is a biopharmaceutical company focused on developing innovative treatments for neurological and endocrine diseases. The company conducts research and creates drug therapies aimed at addressing the unmet medical needs of patients suffering from conditions such as movement disorders, psychiatric disorders, and hormonal disorders. Through a combination of scientific expertise and cutting-edge technology, Neurocrine strives to enhance patient outcomes and improve quality of life, while expanding its pipeline of therapeutic options in the field of neuroscience and endocrinology. Read More
Neurocrine Biosciences exemplifies GARP investing, blending strong earnings growth, solid profitability, and a reasonable stock price within its sector.
Discover NBIX, a top momentum stock with accelerating EPS growth of 64.5%, rising profit margins, and a perfect technical rating for a potential breakout.
